Cipher Pharmaceuticals has introduced Beteflam (betamethasone valerate) in Canada to treat patients with mild to moderate plaque psoriasis.
The company licensed the Canadian rights to Beteflam from Swiss firm Institut Biochimique.
The novel, patent-protected Beteflam is indicated for the treatment of mild to moderate plaque psoriasis of the elbows and knees for a maximum duration of 30 days in adult patients.
It is a topical patch that is applied once daily to the affected region and may be cut to fit the particular size and shape of the psoriatic lesion, reducing potential contact of the steroid with healthy areas of the skin.
Cipher Canada general manager Joan Chypyha said: "We are pleased to introduce Beteflam, a unique treatment option for Canadians suffering from plaque psoriasis, a very common and persistent skin disorder, affecting as many as a million Canadians.
"We continue to deliver on our portfolio expansion plans and our commitment to delivering unique dermatology products.
"Beteflam represents our fourth marketed product, and we expect to continue our growth with six products targeted for the Canadian market in 2016 and eight in 2017."
According to the company, topical corticosteroids are currently considered the primary treatment for steroid-responsive inflammatory skin diseases, including mild to moderate chronic plaque psoriasis.
Occlusion dressing with plastic films is said to enhance topical corticosteroids’ efficacy, especially in the treatment of psoriasis.
The efficacy of Beteflam has been evaluated in two randomised, active-controlled studies. Clinical efficacy of Beteflam was found to be superior to betamethasone valerate 0.1% cream and comparable to Dovobet 50µg calcipotriol plus 0.5mg betamethasone dipropionate ointment.
Last year, Cipher completed seven transactions that include the acquisition of Innocutis and its nine branded dermatology products to build its US commercial presence, expand its Canadian dermatology franchise and broaden its pipeline.